{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:25:31Z","timestamp":1791044731043,"version":"4.1.0"},"reference-count":59,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Microangiopathic hemolytic anemia (MAHA) with thrombocytopenia, suggests a thrombotic microangiopathy (TMA), linked with thrombus formation affecting small or larger vessels. In cancer patients, it may be directly related to the underlying malignancy (initial presentation or progressive disease), to its treatment, or a separate incidental diagnosis. It is vital to differentiate incidental thrombotic thrombocytopenia purpura or atypical hemolytic uremic syndrome in cancer patients presenting with a TMA, as they have different treatment strategies, and prompt initiation of treatment impacts outcome. In the oncology patient, widespread microvascular metastases or extensive bone marrow involvement can cause MAHA and thrombocytopenia. A disseminated intravascular coagulation (DIC) picture may be precipitated by sepsis or driven by the cancer itself. Cancer therapies may cause a TMA, either dose-dependent toxicity, or an idiosyncratic immune-mediated reaction due to drug-dependent antibodies. Many causes of TMA seen in the oncology patient do not respond to plasma exchange and, where feasible, treatment of the underlying malignancy is important in controlling both cancer-TMA or DIC driven disease. Drug-induced TMA should be considered and any putative causal agent stopped. We will discuss the differential diagnosis and treatment of MAHA in patients with cancer using clinical cases to highlight management principles.<\/jats:p>","DOI":"10.1182\/blood.2019003810","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T22:04:59Z","timestamp":1611266699000},"page":"1310-1317","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":64,"title":["How I treat microangiopathic hemolytic anemia in patients with cancer"],"prefix":"10.1182","volume":"137","author":[{"given":"M. R.","family":"Thomas","sequence":"first","affiliation":[{"name":"Department of Haematology, University College London Hospital, Cardiometabolic Programme-NIHR UCLH\/UCL BRC, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Scully","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Hospital, Cardiometabolic Programme-NIHR UCLH\/UCL BRC, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2021031116253034000_B1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"issue":"4","key":"2021031116253034000_B2","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"issue":"1","key":"2021031116253034000_B3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/rth2.12160","article-title":"Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine","volume":"3","author":"Coppo","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"2021031116253034000_B4","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/bjh.12975","article-title":"Measurement of non-coumarin anticoagulants and their effects on tests of haemostasis: guidance from the British Committee for Standards in Haematology","volume":"166","author":"Kitchen","year":"2014","journal-title":"Br J Haematol"},{"issue":"6","key":"2021031116253034000_B5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1200\/JOP.2016.012096","article-title":"Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer","volume":"12","author":"Morton","year":"2016","journal-title":"J Oncol Pract"},{"issue":"2","key":"2021031116253034000_B6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2141.1970.tb01433.x","article-title":"Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma","volume":"18","author":"Brain","year":"1970","journal-title":"Br J Haematol"},{"issue":"4","key":"2021031116253034000_B7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ajh.20783","article-title":"Management of cancer-associated thrombotic microangiopathy: what is the right approach?","volume":"82","author":"Werner","year":"2007","journal-title":"Am J Hematol"},{"issue":"6","key":"2021031116253034000_B8","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1200\/JCO.1989.7.6.781","article-title":"Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry","volume":"7","author":"Lesesne","year":"1989","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021031116253034000_B9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases","volume":"91","author":"Lechner","year":"2012","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2021031116253034000_B10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/sj.thj.6200378","article-title":"Intravascular lymphoma - a rare cause of hemolytic anemia and neurologic disorders","volume":"5","author":"Weisel","year":"2004","journal-title":"Hematol J"},{"issue":"5","key":"2021031116253034000_B11","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/1097-0142(19950301)75:5<1167::AID-CNCR2820750517>3.0.CO;2-1","article-title":"Angiotropic large cell lymphoma presenting as thrombotic microangiopathy (thrombotic thrombocytopenic purpura)","volume":"75","author":"Sill","year":"1995","journal-title":"Cancer"},{"issue":"1","key":"2021031116253034000_B12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000494753","article-title":"Hemolytic anemia of malignancy: a case study involving signet ring cell metastatic breast cancer with severe microangiopathic hemolytic anemia","volume":"12","author":"Lee","year":"2019","journal-title":"Case Rep Oncol"},{"issue":"2","key":"2021031116253034000_B13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.14740\/jh386e","article-title":"A metastatic signet ring cell carcinoma presented as acquired thrombotic thrombocytopenic purpura: a case report","volume":"7","author":"Eisa","year":"2018","journal-title":"J Hematol (Brossard)"},{"issue":"1","key":"2021031116253034000_B14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1600-0609.2010.01448.x","article-title":"Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration","volume":"85","author":"Elliott","year":"2010","journal-title":"Eur J Haematol"},{"issue":"10","key":"2021031116253034000_B15","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.2217\/fon.14.113","article-title":"Metastatic cancer-related thrombotic microangiopathies: a cohort study","volume":"10","author":"Ducos","year":"2014","journal-title":"Future Oncol"},{"issue":"3","key":"2021031116253034000_B16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12029-010-9204-6","article-title":"Disseminated carcinoma diagnosed by bone marrow biopsy in patients with microangiopathic hemolytic anemia and thrombocytopenia: a report of two cases with gastric cancer and a review of the literature","volume":"42","author":"Kaidar-Person","year":"2011","journal-title":"J Gastrointest Cancer"},{"issue":"6","key":"2021031116253034000_B17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"issue":"1","key":"2021031116253034000_B18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/trf.13877","article-title":"A single-center prospective study on the safety of plasma exchange procedures using a double-viral-inactivated and prion-reduced solvent\/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy","volume":"57","author":"Vendramin","year":"2017","journal-title":"Transfusion"},{"issue":"4","key":"2021031116253034000_B19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"2021031116253034000_B20","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjh.12907","article-title":"Malignancy and thrombotic microangiopathy or atypical haemolytic and uraemic syndrome?","volume":"166","author":"Favre","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"2021031116253034000_B21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.2009.07600.x","article-title":"Guidelines for the diagnosis and management of disseminated intravascular coagulation","volume":"145","author":"Levi","year":"2009","journal-title":"Br J Haematol"},{"issue":"2","key":"2021031116253034000_B22","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1182\/blood-2005-03-1087","article-title":"Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure","volume":"107","author":"Ono","year":"2006","journal-title":"Blood"},{"issue":"3","key":"2021031116253034000_B23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1182\/blood.V79.3.543.543","article-title":"Reassessing the hemostatic disorder associated with acute promyelocytic leukemia","volume":"79","author":"Tallman","year":"1992","journal-title":"Blood"},{"issue":"9","key":"2021031116253034000_B24","doi-asserted-by":"crossref","first-page":"E348","DOI":"10.1002\/ajh.24447","article-title":"Proteasome inhibitor associated thrombotic microangiopathy","volume":"91","author":"Yui","year":"2016","journal-title":"Am J Hematol"},{"issue":"9","key":"2021031116253034000_B25","doi-asserted-by":"crossref","first-page":"E218","DOI":"10.1002\/ajh.25832","article-title":"Proteasome inhibitor-associated thrombotic microangiopathy: a review of cases reported to the FDA adverse event reporting system and published in the literature","volume":"95","author":"Nguyen","year":"2020","journal-title":"Am J Hematol"},{"issue":"6","key":"2021031116253034000_B26","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/ejh.13401","article-title":"Carfilzomib-induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: a retrospective study","volume":"104","author":"Kozlowski","year":"2020","journal-title":"Eur J Haematol"},{"key":"2021031116253034000_B27","first-page":"7063145","article-title":"Drug-induced thrombotic microangiopathy due to cumulative toxicity of ixazomib","volume":"2018","author":"Atallah-Yunes","year":"2018","journal-title":"Case Rep Hematol"},{"issue":"1","key":"2021031116253034000_B28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/jth.13189","article-title":"The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies","volume":"14","author":"Phillips","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2021031116253034000_B29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2141.2009.07916.x","article-title":"Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom","volume":"148","author":"Taylor","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"2021031116253034000_B30","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"2021031116253034000_B31","doi-asserted-by":"crossref","first-page":"106195","DOI":"10.1016\/j.leukres.2019.106195","article-title":"A review of thrombotic microangiopathies in multiple myeloma","volume":"85","author":"Portuguese","year":"2019","journal-title":"Leuk Res"},{"key":"2021031116253034000_B32","doi-asserted-by":"crossref","first-page":"bjh.16796","DOI":"10.1111\/bjh.16796","article-title":"Complement as the enabler of carfilzomib-induced thrombotic microangiopathy","author":"Blasco","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"2021031116253034000_B33","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2021031116253034000_B34","doi-asserted-by":"crossref","first-page":"794","DOI":"10.7326\/0003-4819-132-10-200005160-00005","article-title":"Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura","volume":"132","author":"Tsai","year":"2000","journal-title":"Ann Intern Med"},{"issue":"3","key":"2021031116253034000_B35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s13730-020-00454-0","article-title":"Thrombotic thrombocytopenic purpura associated to dual checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Lafranchi","year":"2020","journal-title":"CEN Case Rep"},{"issue":"1","key":"2021031116253034000_B36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40425-017-0224-7","article-title":"Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)","volume":"5","author":"King","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2021031116253034000_B37","first-page":"2464619","article-title":"Thrombotic thrombocytopenic purpura due to checkpoint inhibitors","volume":"2018","author":"Youssef","year":"2018","journal-title":"Case Rep Hematol"},{"issue":"2","key":"2021031116253034000_B38","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/bjh.16333","article-title":"Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature","volume":"188","author":"Elessa","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"2021031116253034000_B39","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ajh.21646","article-title":"TTP disease course is independent of myeloma treatment and response","volume":"85","author":"Hofmeister","year":"2010","journal-title":"Am J Hematol"},{"issue":"9","key":"2021031116253034000_B40","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s00277-015-2421-0","article-title":"Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma","volume":"94","author":"Cheah","year":"2015","journal-title":"Ann Hematol"},{"issue":"9","key":"2021031116253034000_B41","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.3109\/10428194.2014.914203","article-title":"Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide","volume":"55","author":"Montefusco","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2021031116253034000_B42","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/bcp.13808","article-title":"Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort","volume":"85","author":"Daviet","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"2021031116253034000_B43","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"2021031116253034000_B44","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMra066469","article-title":"Drug-induced immune thrombocytopenia","volume":"357","author":"Aster","year":"2007","journal-title":"N Engl J Med"},{"issue":"31","key":"2021031116253034000_B45","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1200\/JCO.2012.42.5082","article-title":"Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review","volume":"30","author":"Niu","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021031116253034000_B46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000495031","article-title":"Treatment of chemotherapy-induced thrombotic microangiopathy with eculizumab in a patient with metastatic breast cancer","volume":"12","author":"Hausberg","year":"2019","journal-title":"Case Rep Oncol"},{"issue":"1","key":"2021031116253034000_B47","first-page":"E30","article-title":"Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review","volume":"5","author":"Al Ustwani","year":"2014","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"2021031116253034000_B48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12882-018-0812-x","article-title":"The use of eculizumab in gemcitabine induced thrombotic microangiopathy","volume":"19","author":"Krishnappa","year":"2018","journal-title":"BMC Nephrol"},{"issue":"7","key":"2021031116253034000_B49","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.21873\/anticanres.14393","article-title":"Rapid improvement in gemcitabine-associated thrombotic microangiopathy after a single dose of eculizumab: case report and review of the literature","volume":"40","author":"Burns","year":"2020","journal-title":"Anticancer Res"},{"issue":"01","key":"2021031116253034000_B50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5414\/CNCS109836","article-title":"Eculizumab in chemotherapy-induced thrombotic microangiopathy","volume":"8","author":"Schulte-Kemna","year":"2020","journal-title":"Clin Nephrol Case Stud"},{"key":"2021031116253034000_B51","article-title":"Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies","author":"Khosla","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2021031116253034000_B52","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"key":"2021031116253034000_B53","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/asheducation-2018.1.371","article-title":"Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria","volume":"2018","author":"Merrill","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"2021031116253034000_B54","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy","volume":"127","author":"Jodele","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2021031116253034000_B55","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","author":"Jodele","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2021031116253034000_B56","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"2021031116253034000_B57","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1182\/bloodadvances.2017008250","article-title":"In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy","volume":"1","author":"Rotz","year":"2017","journal-title":"Blood Adv"},{"key":"2021031116253034000_B58","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/asheducation-2017.1.651","article-title":"Thrombocytopenia in hospitalized patients: approach to the patient with thrombotic microangiopathy","volume":"2017","author":"Scully","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021031116253034000_B59","doi-asserted-by":"crossref","first-page":"9410727","DOI":"10.1155\/2017\/9410727","article-title":"Pernicious anemia associated cobalamin deficiency and thrombotic microangiopathy: case report and review of the literature","volume":"2017","author":"Yousaf","year":"2017","journal-title":"Case Rep Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/10\/1310\/1802078\/bloodbld2019003810c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/10\/1310\/1802078\/bloodbld2019003810c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T20:31:01Z","timestamp":1724358661000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/10\/1310\/475029\/How-I-treat-microangiopathic-hemolytic-anemia-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,3,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019003810","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,11]]}}}